Session » (1996–2018) Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

Date: Tuesday, November 14, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

9:00AM-11:00AM: Abstract Number: 1997

A Randomized, Double-blind, Phase III Study to Compare SB16 (Proposed Denosumab Biosimilar) to Reference Denosumab in Patients with Postmenopausal Osteoporosis

9:00AM-11:00AM: Abstract Number: 2010

B-FROST: Chronic OBstructive Pulmonary Disease and Vertebral FRacture of OSTeoporotic Origin: Results of a Real-life Cohort

9:00AM-11:00AM: Abstract Number: 2004

Bone Health Following Bariatric Surgery: A Single Center Quality Improvement Study

9:00AM-11:00AM: Abstract Number: 2001

Burden of Metabolic Bone Disease in Patients with IgG4-Related Disease with and Without Autoimmune Pancreatitis

9:00AM-11:00AM: Abstract Number: 2013

Clinical Characteristics and Risk Factors Associated with Fragility Fractures in Patients with Primary and Idiopathic Mast Cell Activation Syndromes

9:00AM-11:00AM: Abstract Number: 2008

Comparative Effectiveness of Denosumab versus Alendronate Among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program

9:00AM-11:00AM: Abstract Number: 2002

Cost-Effectiveness Analysis of Sequential Treatment with Abaloparatide Followed by Alendronate in US Women and Men with Multiple Previous Fractures

9:00AM-11:00AM: Abstract Number: 2018

Development of an Osteoporosis Treatment Gap Dashboard

9:00AM-11:00AM: Abstract Number: 2003

Effects of Abaloparatide on Cortical and Trabecular Compartments by 3D-DXA in Men with Osteoporosis

9:00AM-11:00AM: Abstract Number: 2007

Effects of IL-17 Blockade on Skeletal Microarchitecture in Patients with Axial Spondyloarthritis: An HR-pQCT Study

9:00AM-11:00AM: Abstract Number: 2000

Efficacy of Romosozumab for Glucocorticoid-induced Osteoporosis in Patients with Rheumatic Diseases; A Prospective Study

9:00AM-11:00AM: Abstract Number: 2016

Generation of a Human 3D in Vitro Bone Model That Mimics Glucocorticoid-induced Osteoporosis

9:00AM-11:00AM: Abstract Number: 1998

How to Tailor Osteoporosis Therapies in Patients with Advanced Liver Disease? Variations of Renal Function by Creatinine and Cystatin C

9:00AM-11:00AM: Abstract Number: 2006

Improvement of Care: Osteoporosis Screening in a Resident-led Primary Care Clinic

9:00AM-11:00AM: Abstract Number: 2012

Incidence of Hyperparathyroidism in Patients with Osteoporosis Treated with Zoledronic Acid or Denosumab

9:00AM-11:00AM: Abstract Number: 2017

Lupus Nephritis Is Strongly Associated with Low Bone Mineral Density and Osteoporosis in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1999

One-year Incidence of Clinical Fragility Fractures After Implementing an Osteoporosis Care Protocol in Patients Eligible for Liver Transplantation

9:00AM-11:00AM: Abstract Number: 2011

Predicting Fractures in Patients with Isolated Lumbar Spine Osteoporosis Compared to Those with Isolated Hip Osteoporosis

9:00AM-11:00AM: Abstract Number: 2009

Screening and Treatment of Low Bone Mineral Density in Allogeneic Hematopoietic Cell Transplant Patients

9:00AM-11:00AM: Abstract Number: 2005

Secondary Prevention of Osteoporosis in Hip Fracture Care for Elderly Patients. Clinical and Functional Profile of Users

9:00AM-11:00AM: Abstract Number: 2015

Synergistic Effect Between Denosumab and Immune Checkpoint Inhibitors : A Retrospective Study of 268 Patients with Bone Metastases

9:00AM-11:00AM: Abstract Number: 2014

The Role of Orosomucoid 2 in the Regulation of Bone Remodeling by Inhibiting Osteoclastogenesis and Promoting Osteogenesis

9:00AM-11:00AM: Abstract Number: 1996

Variation in Dual-energy X-ray Absorptiometry Reporting: A National Survey of Veterans Health Administration Clinics

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].